Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15757221 | 0.89 | POLB (0.46) | POLBAPEX1HPGDSMN1; SMN2MAPT | |
| SCHEMBL2630704 | 0.89 | POLB (0.46) | POLBAPEX1HPGDSMN1; SMN2MAPT | |
| SCHEMBL19433388 | 0.85 | POLB (0.43) | POLBAPEX1HPGDSMN1; SMN2MAPT | |
| SCHEMBL10625992 | 0.85 | TSHR (0.44) | POLBAPEX1HPGDSMN1; SMN2MAPT | |
| SCHEMBL690412 | 0.84 | POLB (0.46) | POLBAPEX1HPGDSMN1; SMN2MAPT | |
| SCHEMBL29997409 | 0.84 | POLB (0.46) | POLBAPEX1HPGDSMN1; SMN2MAPT | |
| SCHEMBL23301697 | 0.84 | POLB (0.42) | POLBAPEX1HPGDSMN1; SMN2MAPT | |
| SCHEMBL9053212 | 0.84 | KEAP1 (0.43) | POLBAPEX1HPGDSMN1; SMN2MAPT | |
| SCHEMBL9025713 | 0.84 | POLB (0.42) | POLBAPEX1HPGDSMN1; SMN2MAPT | |
| SCHEMBL31462929 | 0.84 | POLB (0.42) | POLBAPEX1HPGDSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5068449-A | FLUORINATED BENZOYL COMPOUNDS | ASAHI GLASS COMPANY, LTD. (JP) | 1991-11-26 | — | — | US | claimed |
| EP-0342849-A2 | Intermediates for preparing 1,4-dihydro-4-oxo-quinoline-3-carboxylic acid esters | PFIZER INC. (US) | 1989-11-23 | — | — | EP | claimed |
| EP-0303291-A2 | Fluorinated benzoyl compounds | ASAHI GLASS COMPANY LTD. (JP) | 1989-02-15 | — | — | EP | claimed |
| JP-1045332-A | — | — | None | — | — | JP | disclosed |
| EP-2114906-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8604061-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO | 2010-05-13 | — | — | US | disclosed |
| EP-2114906-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-0303291-B1 | Fluorinated benzoyl compounds | ASAHI GLASS CO LTD (JP) | 1995-04-26 | — | — | EP | disclosed |
| EP-0411252-B1 | Process for the preparation of fluorobenzoic acids | RIEDEL DE HAEN AG (DE) | 1993-11-03 | — | — | EP | disclosed |
| US-5093515-A | Intermediate for quinolone carboxylic acid bactericide | ASAHI GLASS COMPANY LTD. (JP) | 1992-03-03 | — | — | US | disclosed |
| US-5093529-A | Process for the preparation of fluorinated benzoic acids | CASSELLA AKTIENGESELLSCHAFT (DE) | 1992-03-03 | — | — | US | disclosed |
| US-5068449-A | FLUORINATED BENZOYL COMPOUNDS | ASAHI GLASS COMPANY, LTD. (JP) | 1991-11-26 | — | — | US | disclosed |
| US-4994610-A | Process for preparing fluorinated benzoyl compounds | ASAHI GLASS COMPANY, LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| EP-0411252-A1 | Process for the preparation of fluorobenzoic acids | RIEDEL-DE HAEN AKTIENGESELLSCHAFT (DE) | 1991-02-06 | — | — | EP | disclosed |
| EP-0342849-A2 | Intermediates for preparing 1,4-dihydro-4-oxo-quinoline-3-carboxylic acid esters | PFIZER INC. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0303291-A2 | Fluorinated benzoyl compounds | ASAHI GLASS COMPANY LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | POLB 3079/4885APEX1 3347/4885HPGD 3898/4885 |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | POLB 3014/4885APEX1 3393/4885HPGD 3835/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | POLB 3079/4885APEX1 3347/4885HPGD 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.